Market Cap 206.04M
Revenue (ttm) 57.80M
Net Income (ttm) -97.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -169.45%
Debt to Equity Ratio 0.00
Volume 4,668,700
Avg Vol 5,664,196
Day's Range N/A - N/A
Shares Out 301.71M
Stochastic %K 65%
Beta 1.22
Analysts Strong Sell
Price Target $4.10

Company Profile

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 970 6000
Address:
501 Canal Blvd, Richmond, United States
Dude1234
Dude1234 Oct. 7 at 12:36 PM
$SGMO I ran chat GPT to see what a genetic cure for Alzheimers would be worth Best case was 20 to 50 billion a year in revenue, but interesting part was peak sales would be 2035 to 2045 it said that was probably due to demographics found that part really interesting. GLTA.
0 · Reply
Bio2Retire
Bio2Retire Oct. 7 at 12:15 PM
$SGMO Can someone email Sandy and see if he is still working
1 · Reply
Andi422
Andi422 Oct. 7 at 12:01 PM
1 · Reply
John8886
John8886 Oct. 7 at 11:32 AM
0 · Reply
hamm461
hamm461 Oct. 7 at 11:22 AM
0 · Reply
biotech
biotech Oct. 7 at 11:12 AM
0 · Reply
biotech
biotech Oct. 7 at 11:12 AM
0 · Reply
biotech
biotech Oct. 7 at 11:11 AM
0 · Reply
TwoThirdsProbablyDown
TwoThirdsProbablyDown Oct. 7 at 10:59 AM
$SGMO Are we there yet?
1 · Reply
Dude1234
Dude1234 Oct. 7 at 9:22 AM
$SGMO Just something I've wondered about. A gene therapy should have much longer patent protection/ exclusivity, because it's much harder to produce a so called generic version, if not near imposible even actually? Ran Chat GPT on this. Yes — gene therapies are much harder to make a generic (or “biosimilar”) version of compared to traditional small-molecule drugs. Here’s why: 🧬 1. Complexity of the Product Small-molecule drugs (like aspirin or statins) are chemically simple and can be exactly replicated. Generic manufacturers just need to prove their version is chemically identical. Gene therapies, on the other hand, involve large, biologically active molecules (e.g., viral vectors carrying genetic payloads). These are produced in living cells, so it’s virtually impossible to make an exact copy — only something “highly similar.”
0 · Reply
Latest News on SGMO
Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call

Jul 31, 2025, 4:05 PM EDT - 2 months ago

Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call


Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

May 6, 2025, 4:35 PM EDT - 5 months ago

Sangamo Therapeutics Announces First Quarter 2025 Earnings Call


Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet

Dec 31, 2024, 12:01 PM EST - 9 months ago

Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet


Dude1234
Dude1234 Oct. 7 at 12:36 PM
$SGMO I ran chat GPT to see what a genetic cure for Alzheimers would be worth Best case was 20 to 50 billion a year in revenue, but interesting part was peak sales would be 2035 to 2045 it said that was probably due to demographics found that part really interesting. GLTA.
0 · Reply
Bio2Retire
Bio2Retire Oct. 7 at 12:15 PM
$SGMO Can someone email Sandy and see if he is still working
1 · Reply
Andi422
Andi422 Oct. 7 at 12:01 PM
1 · Reply
John8886
John8886 Oct. 7 at 11:32 AM
0 · Reply
hamm461
hamm461 Oct. 7 at 11:22 AM
0 · Reply
biotech
biotech Oct. 7 at 11:12 AM
0 · Reply
biotech
biotech Oct. 7 at 11:12 AM
0 · Reply
biotech
biotech Oct. 7 at 11:11 AM
0 · Reply
TwoThirdsProbablyDown
TwoThirdsProbablyDown Oct. 7 at 10:59 AM
$SGMO Are we there yet?
1 · Reply
Dude1234
Dude1234 Oct. 7 at 9:22 AM
$SGMO Just something I've wondered about. A gene therapy should have much longer patent protection/ exclusivity, because it's much harder to produce a so called generic version, if not near imposible even actually? Ran Chat GPT on this. Yes — gene therapies are much harder to make a generic (or “biosimilar”) version of compared to traditional small-molecule drugs. Here’s why: 🧬 1. Complexity of the Product Small-molecule drugs (like aspirin or statins) are chemically simple and can be exactly replicated. Generic manufacturers just need to prove their version is chemically identical. Gene therapies, on the other hand, involve large, biologically active molecules (e.g., viral vectors carrying genetic payloads). These are produced in living cells, so it’s virtually impossible to make an exact copy — only something “highly similar.”
0 · Reply
MakingMoneyHere
MakingMoneyHere Oct. 7 at 6:54 AM
$SGMO I don't know what kind of deals you're expecting here, but I expect news to come out that a lawsuit has been filed against them. 🤣
0 · Reply
notnowson
notnowson Oct. 7 at 2:17 AM
$SGMO SANDY
0 · Reply
Prittykitty
Prittykitty Oct. 7 at 12:07 AM
$SGMO crsp basing for years. Gonna go 100 in 2026. Most GE companies getting supercharged. A rising tide lifts all boats. Entering the beginning of gene therapy as normality.
1 · Reply
Swamp_Yankee
Swamp_Yankee Oct. 6 at 11:27 PM
$SGMO https://www.txs.uscourts.gov/page/bankruptcy-court
0 · Reply
Swamp_Yankee
Swamp_Yankee Oct. 6 at 11:26 PM
$SGMO Sandy, hard at work!
0 · Reply
809trader
809trader Oct. 6 at 11:22 PM
$SGMO nice volume after hours
0 · Reply
Swamp_Yankee
Swamp_Yankee Oct. 6 at 11:20 PM
$SGMO The kooks on this board have turned to bashing shareholders. Well done! As the company and pathetic CEO dries you out and ends up in bankruptcy where you will get fucked so hard you won't know what to do. LMFAO.
0 · Reply
Crash_Bash
Crash_Bash Oct. 6 at 10:44 PM
$SGMO is tomorrow the day? Sandy you love Tuesdays PRs lets do it foe all the investors that have waited this long.
0 · Reply
John8886
John8886 Oct. 6 at 10:04 PM
$SGMO Honest guess is that they diluted already
0 · Reply
John8886
John8886 Oct. 6 at 9:54 PM
$SGMO Its so frustrating to look at the broader market and here we are groundhogin every single day, imma press the bearish button for the first time. Expecting dilution again.
0 · Reply
Swamp_Yankee
Swamp_Yankee Oct. 6 at 9:45 PM
$SGMO It's going to be difficult for me not to dump a shit ton of shares tomorrow. At least 50 to 75k. There's too much money to be made elsewhere. Sandy and Sangamo are a disaster.
2 · Reply
Spider217
Spider217 Oct. 6 at 7:47 PM
$SGMO For Sandy as CEO to go radio silent when his company is on the brink of disaster is unbelievable. No respect for all of us who are loyal shareholders. I cannot believe the board of directors who are supposed to protect shareholders interest are sitting quietly. I am a large shareholder for a long time but we do need clarity on this like yesterday. The board has to react!!!
3 · Reply